Telix Pharmaceuticals upgrades full-year revenue target to $1.2b as third quarter surges

A surge in September-quarter earnings has led Melbourne-based Telix Pharmaceuticals’ (ASX: TLX) to upgrade its full-year revenue forecast to a high of US$820 million ($1.26 billion) as the company’s growth was driven by the launch of new products into the market over the past year.

Telix has…


Click here to view the original article.